GHRL and Parkinson disease: Both SCFA and ghrelin have a neuroprotective function, so their reduced levels observed in patients with PD can be considered not only as one of the critical factors of PD but also potentially reflect disease severity (Hill-Burns et al., 2017; Song et al., 2017; Elfil et al., 2020).